

# Role of Cat-App in Concawe REACH strategy for human health

Cat-App final event, Brussels, 6 September 2018

*Hans Ketelslegers, Science Executive Health, Concawe*



# Agenda

- 01 Petroleum UVCBs
- 02 Mammalian toxicology of petroleum substances
- 03 Datagaps, Cat-App and the Concawe REACH strategy for human health




1

# Petroleum UVCBs


A regulatory toxicology challenge

# Petroleum substances: a regulatory (toxicology) challenge




- 207 Petroleum Substances (PS)
- Thousands to millions of molecules (isomers) per PS
- UVCB
  - Unknown or
  - Variable composition,
  - Complex reaction products,
  - Biological materials

# Fractionation and Processing of Crude Oil into Petroleum Substances (Complex [reaction] products of Biological origin)




# Fractionation Process Yields Complex Reaction Products, with "neighboring" streams overlapping

- Fractionated distillation splits a feed stream into product streams with constituents preferentially distilling according to their boiling points.
- Due to imperfect separation each product stream includes compounds with true boiling points outside the intended boiling point range.



## Example

- The fractionation scheme for the fictional unit illustrated above could result in product constituent distributions as below, indicated by boiling point ranges



Petroleum Substances are UVCBs

- Unknown or
- Variable composition,
- Complex reaction products,
- Biological materials

# Petroleum Substances are Variable in Composition

Stream composition varies continuously over time due to several factors


- Feedstock composition
- Processing severity
- Separation temperatures, sharpness
- Catalyst / equipment performance

Variation is limited due to performance specifications of the final products

- Specified by substance identity

## Example

- Illustration below based on light distillate fraction (previous slide)



Petroleum Substances are UVCBs

- Unknown or
- **Variable composition,**
- Complex reaction products,
- Biological materials

# Petroleum Substances have Complex Chemical Composition of which a large part is Unknown

- The number of individual constituents increases rapidly with carbon number
  - (\*) Including aromatics would increase the number of isomer molecules dramatically
- The predominant constituents are described by carbon number/boiling point ranges and hydrocarbon types
- Carbon number/boiling point ranges are influenced by fractionation
- Hydrocarbon types (n-/i-alkanes, aromatics, olefins, etc.) are influenced by chemical processing
- Petroleum UVCB can never be fully characterized analytically

C number	Boiling point °C (n-alkanes) (*)	Number of isomers (alkanes only!)
3	-42	1
4	-1	2
5	36	3
6	69	5
7	98	9
8	126	18
10	174	75
15	269	4 347
20	343	366 231
25	402	36 777 419
30	450	4 108 221 447
35	490	493 054 243 760
40	525	62 353 826 654 563

Naphthas (Gasoline)

Gas oils

Heavy products

This table is for illustrative purposes only

Petroleum Substances are UVCBs

- **Unknown** or
- Variable composition,
- Complex reaction products,
- Biological materials





# 2

## Mammalian toxicology of petroleum products

Toxicological hazards and PAH based testing hypothesis for grouping and read across assessments

# Petroleum substances: a regulatory (toxicology) challenge



16.8.67

OFFICIAL JOURNAL OF THE EUROPEAN COMMUNITIES

No 196/1

## COUNCIL DIRECTIVE

of 27 June 1967

on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances

(67/548/EEC)



- 207 Petroleum Substances (PS)
- **Thousands to millions of molecules (isomers) per PS**
- UVCB
  - **Unknown or**
  - **Variable composition,**
  - **Complex reaction products,**
  - **Biological materials**

IUCLID 6

File Edit User Admin Plugins Help

Navigation panel

Search TOC Annotations

REACH Complete table of contents

Text filter

- Concawe IUCLID 6
  - 1 General information
  - 2 Classification & Labelling and PBT assessment
  - 3 Manufacture, use and exposure
  - 4 Physical and chemical properties
  - 5 Environmental fate and pathways
  - 6 Ecotoxicological information
  - 7 Toxicological information**
  - 8 Analytical methods
  - 9 Residues in food and feedingstuffs
  - 10 Effectiveness against target organisms
  - 11 Guidance on safe use
  - 12 Literature search
  - 13 Assessment reports
  - 14 Information requirements

Concawe IUCLID 6

Template name\*  
Concawe IUCLID 6

Remarks

Legal entity flags

Legal entity\*  
CONCAWE A.I.S.B.L. / Brussels / Belgium


Information panel

Information Clipboard manager Attachments Modification history Annotations References

SuperUser

IUCLID 6 example  
*Overview of dossier elements*

# HH endpoints in REACH dossier




The screenshot shows the IUCLID 6 software interface. The main window displays the 'REACH Complete table of contents' with a tree view of toxicological information. The '7 Toxicological information' section is expanded, showing sub-sections like 7.1 Toxicokinetics, 7.2 Acute Toxicity, 7.3 Irritation / corrosion, 7.4 Sensitisation, 7.5 Repeated dose toxicity, 7.6 Genetic toxicity, 7.7 Carcinogenicity, 7.8 Toxicity to reproduction, and 7.9 Specific investigations. The 'Information panel' at the bottom shows tabs for Information, Clipboard manager, Attachments, Modification history, Annotations, and References. The user is logged in as SuperUser.

- Concawe has completed endpoints with historical data, and some newly generated
- These historical data are currently being challenged by ECHA
  - Exposure route (dermal / inh. vs required oral)
  - Non-standard guideline / test quality
  - Compositional description test substance
- Concawe will defend historical data...
- ...while acknowledging there are datagaps which need to be addressed to keep dossiers compliant

# All (hazard) data on PS available in Concawe REACH dossiers

## Example of Low Boiling Point Naphthas (Gasolines)




- Example of ONE tox study summarized in IUCLID and the CSR.
- There are >550 studies (phys/chem, mammalian toxicity, environmental) in total summarized in IUCLID/CSR


*The IUCLID stack of papers is a mock-up. The others are real, printed previously for other reasons.*

*We did not really print the IUCLID file (and don't recommend anyone to print it...)*


# Mammalian toxicological hazards of PS



# Mammalian toxicological hazards of PS



# Concawe PS “Categories”, historically based on refining history



1. **Low Boiling Point Naphthas (Gasolines)**
2. **Kerosines**
3. **Straight-run Gas Oils**
4. **Cracked Gas Oils**
5. **Vacuum Gas Oils, Hydrocracked Gas Oils& Distillate Fuels**
6. **Other Gas Oils**
7. **Heavy Fuel Oil Components**
8. **Unrefined / Acid Treated Oils**
9. **Other Lubricant Base Oils**
10. **Highly Refined Base Oils**
11. **Foots Oils**
12. **Paraffin and Hydrocarbon Waxes**
13. **Slack Wax**
14. **Petrolatum**
15. **Untreated Distillate Aromatic Extracts**
16. **Treated Distillate Aromatic Extracts**
17. **Residual Aromatic Extracts**
18. **Bitumen**

In addition CONCAWE has prepared the joint parts of the Registration Dossier for the following stand-alone substances:

- MK1 diesel fuel (EC number 931-250-7),
- **Oxidised Asphalt (EC number 265-196-4)**
- Sulfur (EC number 231-722-6)

Name	EINECS definition	CAS
Asphalt	A very complex combination of high molecular weight organic compounds containing a relatively high proportion of hydrocarbons having carbon numbers predominantly greater than C25 with high carbon-to-hydrogen ratios. It also contains small amounts of various metals such as nickel, iron, or vanadium. It is obtained as the non-volatile residue from distillation of crude oil or by separation as the raffinate from a residual oil in a deasphalting or decarbonization process.	8052-42-4
Residues (petroleum), vacuum	A complex residuum from the vacuum distillation of the residuum from atmospheric distillation of crude oil. It consists of hydrocarbons having carbon numbers predominantly greater than C34 and boiling above approximately 405°C (723°F).	64741-56-6
Residues (petroleum), hydrodesulfurized vacuum	A complex residuum from the vacuum distillation of the residuum from atmospheric distillation of crude oil, which has been treated with hydrogen and a desulfurizing catalyst to remove sulfur.	
Residues (petroleum), thermal cracked vacuum	A complex residuum from the vacuum distillation of the residuum from atmospheric distillation of crude oil, which has been treated with hydrogen and a desulfurizing catalyst to remove sulfur.	

CAS numbers relate to (last) refining step(s)  
2010 REACH deadline (>1k tonnes):

- large numbers of CAS registered (600+) to
- “secure” company specific refining operations, but
- CAS within a category are eventually describe the “same” petroleum product! (UVCB nature, i.e., “variable” in composition, but variable within product specifications)


-> in general terms: within one petroleum category, CAS numbers describe different ways of making the same substance



# Concawe PS “Categories”, historically based on refining history

Need for improved analytical chemical descriptors on *substance level*


Need for improved biological descriptors (e.g., mechanistic data) on *substance level*



Category or grouping not accepted  
...but worst case read-across OK,  
providing testing hypothesis is proven


# 3-7 ring PAH hypothesis for Petroleum Substances

Based on historical toxicological data<sup>1</sup> it can be stated that the **higher tier mammalian toxicological effects of petroleum substances are associated with the level of 3-7 ring PAH** in poorly refined high boiling petroleum substances



<sup>1</sup> in-vivo toxicological data: see <http://www.petroleumhvp.org/polycyclic-aromatic-compounds> for an exhaustive overview of PAC related toxicity of petroleum substances, including public access to relevant papers. Some selected references are Feuston et al., 1994; McKee et al., 1990; McKee et al., 2012; Schreiner et al., 1997; White 2012

# Testing hypothesis that 3-7 ring PAH cause developmental toxicity




Battery of in-vitro tests in combination with toxicogenomics...

*...to support the 3-7 ring PAH hypothesis*

*...justifying the selection of the worst-case representative for testing*


*...justifying read-across of this test sample to the other group members*

*...eventually underpinning prenatal developmental toxicity of PS with mechanistic data*




# mES assay pilot to support devtox-PAH hypothesis

GTL Reference Oil:  
no aromatics




Kamelia et al., Toxicology in Vitro (2017)


DAE (extracts):  
high (3-7 ring) PAH



Gas Oils (e.g., Diesel):  
low to moderate (3-7 ring) PAH





RAE (aromatic extracts) &  
heavy fuel oil:  
low to high (3-7 ring) PAH



# mES assay pilot to support devtox-PAH hypothesis

In-vitro results correlate with 3-7 ring PAH content, not 2-3 ring PAH...




Kamelia et al., Toxicology in Vitro (2017)

#99 - Distillate aromatic extract (DAE)






... and with in-vivo data




Gas Oils (e.g., Diesel):  
low to moderate (3-7 ring) PAH

RAE (aromatic extracts) &  
heavy fuel oil:  
low to high (3-7 ring) PAH




© Concawe

# AhR CALUX reporter gene assay as further mechanistic support to devtox PAH hypothesis




**Figure 1.** Aromatic Ring Class (ARC) profiles<sup>a</sup> of the DMSO-extracts of PS and GTL tested in the present study.

<sup>a</sup>The weight percent of the DMSO-soluble 1- to  $\geq 7$  aromatic-ring compounds present in each sample, from the starting material of 4.0 gram, as determined by Method II chemical characterization procedure<sup>[4]</sup>.



# PAH reprotox hypothesis project: putting it all together...

- Bioactivity profiling, hierarchical clustering, and chemical ranking using ToxPi GUI 2.0.



- Follow up work will include transcriptomics profiling, and then integrating all data into the overall toxicological WoE to support the Concawe intelligent testing strategy



# 3

## Datagaps and Cat-App

Addressing grouping and read across challenges for (petroleum) UVCBs





# Datagap Analysis - within group

- SRGOs as example -> comprising 4 out of 207 substances (CAS #s)




Human Health Hazard Endpoint

CAS No.	64741-43-1	64741-44-2	68814-87-9	68815-86-8
Name	Gas oils (petroleum), straight-run	Distillates (petroleum), straight-run middle	Distillates (petroleum), full-range straight-run middle	Distillates (petroleum), heavy straight-run
Concawe Registered substance (Y/N)	Y	Y	Y	Y
8.1 Skin irritation or skin corrosion	Not irritating	Not irritating	Not irritating	Not irritating
8.2 Eye irritation	Not irritating	Not irritating	Not irritating	Not irritating
8.3 Skin sensitisation	Not sensitising	Not sensitising	Not sensitising	Not sensitising
Genetics tests				
8.4.1 In vitro gene mutation study in bacteria	Negative TA98 only (Modified Ames Test)	Weak positive TA98 only	Negative TA98 only (Modified Ames Test)	Negative TA98 only (Modified Ames Test)
8.4.2 In vitro cytogenetic study in mammalian cells	Sister chromatid exchange (CHO) negative -S9, ambiguous +S9 [R-A from OGD - CAS No.64742-80-9]	Sister chromatid exchange (CHO) negative -S9, ambiguous +S9 [R-A from OGD - CAS No.64742-80-9]	Sister chromatid exchange (CHO) negative -S9, ambiguous +S9 [R-A from OGD - CAS No.64742-80-9]	Sister chromatid exchange (CHO) negative -S9, ambiguous +S9 [R-A from OGD - CAS No.64742-80-9]
8.4 In vivo mutagenicity	Negative	Negative rat cytogenetic tests	Negative	Negative
Acute toxicity				
8.5.1 By oral route	LD <sub>50</sub> > 5000 mg/kg	LD <sub>50</sub> > 5000 mg/kg	LD <sub>50</sub> > 5000 mg/kg	LD <sub>50</sub> > 5000 mg/kg
8.5.2 By inhalation	LC <sub>50</sub> > 2530 mg/m <sup>3</sup>	LC <sub>50</sub> > 2530 mg/m <sup>3</sup>	LC <sub>50</sub> > 2530 mg/m <sup>3</sup>	LC <sub>50</sub> > 2530 mg/m <sup>3</sup>
8.5.3 By dermal route	LD <sub>50</sub> > 2000 mg/kg	LD <sub>50</sub> > 2000 mg/kg	LD <sub>50</sub> > 2000 mg/kg	LD <sub>50</sub> > 2000 mg/kg
Repeated dose toxicity				
8.6 Repeated dose toxicity dermal (sub-acute)	28d rat systemic NOAEL > 0.5 mL/kg [dose levels tested: 0, 0.01, 0.10, 0.50 mL/kg]	28d rabbit systemic NOAEL > 2000 mg/kg/day [dose levels tested: 0, 200, 1000, 2000 mg/kg/day]	28d rat and rabbit systemic NOAEL > 2000 mg/kg/day	28d rat and rabbit systemic NOAEL > 2000 mg/kg/day
8.6 Repeated dose toxicity dermal (sub-chronic)	90d NOAEL 30 mg/kg/day [R-A from WHO - CAS No.64741-49-7, dose levels tested: 30, 125, 500 mg/kg/day]	90d NOAEL 30 mg/kg/day [R-A from WHO - CAS No.64741-49-7, dose levels tested: 30, 125, 500 mg/kg/day]	90d NOAEL 30 mg/kg/day [R-A from WHO - CAS No.64741-49-7, dose levels tested: 30, 125, 500 mg/kg/day]	90d NOAEL 30 mg/kg/day [R-A from WHO - CAS No.64741-49-7, dose levels tested: 30, 125, 500 mg/kg/day]
8.6 Repeated dose toxicity inhalation	90d NOAEC ≥ 1710 mg/m <sup>3</sup> (systemic); 880 mg/m <sup>3</sup> (local, lung) [R-A from WHO - CAS No. 68334-30-5 (most likely); dose levels tested: 0, 0.38, 0.88, 1.71 mg/L]	90d NOAEC ≥ 1710 mg/m <sup>3</sup> (systemic); 880 mg/m <sup>3</sup> (local, lung) [R-A from WHO - CAS No. 68334-30-5 (most likely); dose levels tested: 0, 0.38, 0.88, 1.71 mg/L]	90d NOAEC ≥ 1710 mg/m <sup>3</sup> (systemic); 880 mg/m <sup>3</sup> (local, lung) [R-A from WHO - CAS No. 68334-30-5 (most likely); dose levels tested: 0, 0.38, 0.88, 1.71 mg/L]	90d NOAEC ≥ 1710 mg/m <sup>3</sup> (systemic); 880 mg/m <sup>3</sup> (local, lung) [R-A from WHO - CAS No. 68334-30-5 (most likely); dose levels tested: 0, 0.38, 0.88, 1.71 mg/L]
Reproductive toxicity				
8.7.2 Developmental toxicity	NOAEL 50 mg/kg/day [dose levels tested: 0, 50, 250, 500 mg/kg/day]	NOAEL 50 mg/kg/day	NOAEL 50 mg/kg/day	NOAEL 50 mg/kg/day
8.7.3 Fertility	Testing proposed *	Testing proposed *	Testing proposed *	Testing proposed *
Carcinogenicity				
8.9.1 Carcinogenicity study	Not considered a carcinogenic hazard	Weakly tumorigenic on the skin secondary to skin irritation; long latent period. Not considered a carcinogenic hazard	Weak initiator and promoter with borderline effects Not considered a carcinogenic hazard	Not considered a carcinogenic hazard

- Where we have data over multiple CAS in a group: alignment - indicating (biological) similarity
- Datagaps: cannot test all endpoints for each and every CAS across all petroleum streams based on practical (time and testing cost) and animal welfare constraints

Need more pragmatic and informed approach

# Current alternative approaches not always applicable to (petroleum) UVCBs



From ECHA RAAF report (7 March 2017):

All chemical structures involved need to be considered; grouping of substances on the basis of structural similarity must take account of **all constituents**, and the predictions within proposed groups must likewise consider the impact of all constituents.

The analysis described in this document **confirmed the complexity of read-across approaches for multi-constituent substances and UVCBs.**

**More work is needed** to further develop the RAAF based on the findings described in this document.

- Learn from other sectors
  - Approaches available for lower tier endpoints (e.g., irritation, acute tox) and well defined chemicals
- However:
  - Real challenge is with higher tier endpoints and complex, multi-constituent substances

# New Technologies to Underpin Category Approaches and Read-across in Regulatory Programmes



# Cat-App Workflow

## Cat-App work programme

**Cat-App: New technologies to underpin the category approaches and read across in regulatory programmes**

**Project Management:** Hans Ketelslegers, Concawe

**Steering:** Concawe's scientific committee and toxicology subgroup

### WP1

**Organisation of data available on PS**  
(Ivan Rusyn/Texas A&M University)

- 1.1 Obtain, process and share chemical samples
- 1.2 Collect available records (manufacturing process info., phys./chem. properties, analytical chemistry, existing toxicity data on mammalian, ecotox)
- 1.3 Digitise records into flexible and inter-operable database format

### WP2

**Bioactivity screening**  
(Ivan Rusyn/Texas A&M University)

#### WP2.a

(Ivan Rusyn/Texas A&M University)

- High content screening of iPSC\*-derived cells
- Hepatocytes, neurons, cardiomyocytes, macrophages, endothelial

#### WP2.b

(Tim Gant/PHE)

- Toxicity phenotyping in 10 diverse cell lines

### WP3

**High throughput genomics** (Ivan Rusyn/Texas A&M University)

- 3.1 High-throughput transcriptomics profiling of ~11,000 samples for TempO-seq

### WP4

**Perform data integration and chemical biological read across**  
(Fred Wright/NCSU)

#### WP 4.a

(Fred Wright/NCSU)

- 4a.1 Coordinate data management and workflow
- 4a.2 Perform uncertainty and variability analyses
- 4a.3 Process and analyse omics data
- 4a.4 Perform ToxPi analysis

#### WP4.b (Shu-Dong Zhang/Ulster)

- 4b.1 Perform connectivity mapping
- 4b.2 Develop and apply analysis algorithms to robustness testing, investigate grouping accuracy and profiling cost

### WP5

**Dissemination, project administration and Outreach**  
(Klaus Lenz/SYNCOM)

- 5.1 Project Dissemination and website
- 5.2 Project Administration
- 5.3 Outreach

#### Advisory Board

George Daston  
*Procter & Gamble*

Shirley Price  
*University of Surrey*

Chris Rowat  
*Health Canada*

Xiaowei Zhang  
*Nanjing University*

#### Institute abbreviations:

Texas A&M University Research  
- NCSU: North Carolina State University - PHE: Public Health England

Ulster: Ulster University - SYNCOM: SYNCOM R&D consulting GmbH

[www.concawe.eu/cat-app](http://www.concawe.eu/cat-app)

\*induced Pluripotent Stemcells



# Cat-App Workflow

## Cat-App work programme

Cat-App: New technologies to underpin the category approaches and read across in regulatory programmes  
**Project Management:** Hans Ketelslegers, Concawe  
**Steering:** Concawe's scientific committee and toxicology subgroup

### WP1

Setting up database with all available data and infrastructure for data to be generated in the project (and in other Concawe activities?)

Presentation 1 – Ivan Rusyn (TAMU)

Integrative analysis of all available data to support and visualize groupings for transparent communication of all data (eventually supporting chemical-biological read across of available (in-vivo) hazard data to fill datagaps)

Presentation 2 – Fred Wright (NCSU)

### WP2

Evaluation of mechanistic toxicology (e.g. phenotypical) changes in stem cells and human cell-lines in response to PS exposure

Presentation 1 - Ivan Rusyn (TAMU)

The application of reference chemicals in Cat-App to support grouping PS

Presentation 4 – Tim Gant (PHE)

### WP3

Presentation of how gene expression data from the most responsive stem cells and human cell-line models add value to Cat-App

Presentation 3 – Shu-Dong Zhang (TAMU)

Transcriptomics (Ivan Rusyn/Texas A&M)

### Advisory Board

- George Daston  
*Procter & Gamble*
- Shirley Price  
*University of Surrey*
- Chris Rowat

[www.concawe.eu/cat-app](http://www.concawe.eu/cat-app)




© Concawe

# Overview of informed and tiered intelligent testing strategy

Target animal testing where needed as a last resort, based on a worst case approach rather than targeting all substances

## Basis for testing strategy:

- Historical (in-vivo) data
- Mechanistic data
- Available human data
- **Cat-App**



Mutagenicity / Genetox including screening assays

“optimized” OECD 422 screening studies will “connect the dots” between lower and higher tier testing needs,

Carc WoE, including screening assays

Reprotoxicity, including DevTox in-vitro screening battery

Repeated Dose toxicity



# Thought starter for today to “set the scene”:

## Concawe Health REACH: stop at the crossroad and think before we go...

### Test everything

- 207 products, 10-15 endpoints
- Variability – what’s the “definite” answer?!
- batch testing? Every decade or so?
- Millions of animals...
- What do we actually gain?  
(mainly in terms of managing HH risks, product stewardship?)

### Use alternative methods to show that

- Variation is limited and defined
- Refining: “natural PP groupings” (phys / Chem Bioactivity relate)
- We can succeed with selected additional targeted animal testing short term in an intelligent strategy
- We’re not underestimating risk!
  - prove that risks are managed
- Sustainable: batch screening in a cost effective manner, preventing additional unnecessary animal testing long term

- “True” data gaps / historical data “not adequate”?
- When is data “historical” for substances of variable composition ?
- Crude source / refining, leading to
  - truly variable substances or just variable within defined range (product specs)?
  - Holistic Approach: addressing “continuum” of petroleum substances
- How are substances used? How are people potentially exposed?
  - Hazard- vs risk based regulation
- **Test every substance** or take a more realistic and **pragmatic approach?**



Thought starter for today to “set the scene”:

Concawe Health REACH: stop at the crossroad and think before we go...



Risk of getting lost in an endless detour?

Taking “preliminary” regulatory action  
would again ignore the possibility

to make a significant step towards application of NAM data  
in view of “the 3Rs” in a regulatory context

# Take away messages for today

- Petroleum UVCBs are substances (PS), not mixtures, and are highly complex - cannot be fully characterized analytically
- PS form a continuum of substances, based on their refining history; neighboring streams overlap
- Although they therefore are a regulatory challenge, there is a **wealth of historical in-vivo data available**
- Some of these data and **our grouping and read across approach are being challenged**, which could lead to high numbers of (unnecessary) animal testing
- **Read across and testing hypotheses** can be build to address that issue, which are based on the **3-7 ring PAH content in PS**
- Cat-App and other efforts ongoing at Concawe take the opportunities that new approach methodologies provide, **to further support this hypothesis, the grouping of PS and eventually read across of in-vivo data**
- These data will therefore be applied as an integral part of the targeted and **informed testing strategy** for HH REACH endpoints, which is **aimed at minimizing animal testing**

# Thank you for your attention

Hans Ketelslegers

Hans Ketelslegers@concawe.eu



[www.concawe.eu/cat-app](http://www.concawe.eu/cat-app)